Journal
ONCOLOGY RESEARCH
Volume 17, Issue 5, Pages 223-230Publisher
COGNIZANT COMMUNICATION CORP
DOI: 10.3727/096504008786111356
Keywords
5-Aza-2 '-deoxycytidine; Epigenetic; Leukemia; Genistein; Chemotherapy; Drug resistance
Categories
Funding
- Canadian Cancer Society
- Cancer Research Society
Ask authors/readers for more resources
5-Aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylation, is an effective agent for the treatment of leukemia. The aim of this study was to investigate the antileukemic activity of this epigenetic agent in combination with genistein, a nontoxic isoflavone with chemopreventive activity. The combined treatment produced a synergistic loss of clonogenicity in human myeloid (HL-60) and lymphoid (MOLT-3) leukemic cell lines. Genistein alone showed a significant antileukemic activity against murine 5-AZA-CdR-resistant cells, and this effect was enhanced when used in combination with 5-AZA-CdR. The combined treatment also produced a synergistic increase in life span of mice with L1210 leukemia. These results suggest that genistein may have the potential to increase the clinical efficacy of 5-AZA-CdR for the treatment of leukemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available